RP-HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-12. Anything still debated is marked as such rather than presented as settled.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Ovarian cysts such as in polyendocrine metabolic ovarian syndrome (PMOS), the most common cause in women. Adrenal gland tumors, adrenocortical adenomas, and adrenocortical carcinoma, as well as adrenal hyperplasia due to pituitary adenomas (as in Cushing's disease). Inborn errors of steroid metabolism such as in congenital adrenal hyperplasia, most commonly caused by 21-hydroxylase deficiency. Acromegaly and gigantism (growth hormone and IGF-1 excess), usually due to pituitary tumors.
=== EC 1.99.2 Oxygenases (now covered by EC 1.13) === EC 1.99.2.1: deleted, now EC 1.13.11.12, lipoxygenase EC 1.99.2.2: deleted, now EC 1.13.11.1, catechol 1,2-dioxygenase EC 1.99.2.3: deleted, now EC 1.13.11.3, protocatechuate 3,4-dioxygenase EC 1.99.2.4: deleted, now EC 1.13.11.4, gentisate 1,2-dioxygenase EC 1.99.2.5: deleted, now EC 1.13.11.5, homogentisate 1,2-dioxygenase EC 1.99.2.6: deleted, now EC 1.13.99.1, inositol oxygenase
Circulatory system: pumping and channeling blood to and from the body and lungs with heart, blood, blood vessels Digestive system: digestion and processing food with salivary glands, esophagus, stomach, liver, gallbladder, pancreas, intestines, rectum, anus Endocrine system: communication within the body using hormones made by endocrine glands such as the hypothalamus, pituitary gland, pineal gland, thyroid, parathyroid glands, adrenal glands Immune system: the system that fights off disease; composed of leukocytes, tonsils, adenoids, thymus, spleen Integumentary system: skin, hair, nails Lymphatic system: structures involved in the transfer of lymph between tissues and the blood stream, the lymph and the nodes and vessels that transport it Musculoskeletal system: muscles provide movement and a skeleton provides structural support and protection with bones, cartilage, ligaments, tendons Nervous system: collecting, transferring and processing information with brain, spinal cord, nerves Reproductive system: the sex organs; in the female; ovaries, fallopian tubes, uterus, vagina, mammary glands, and in the male; testicles, vas deferens, seminal vesicles, prostate, penis Respiratory system: the organs used for breathing, the pharynx, larynx, trachea, bronchi, lungs, diaphragm Urinary system: kidneys, ureters, bladder, urethra involved in fluid balance, electrolyte balance, and excretion of urine
Sources: en.wikipedia.org
Jean becomes possessed by the Phoenix Force once more and Wolverine has no other choice but to kill her with his claws. Wolverine learns about the existence of X-23. He initially believes her to be a clone, raised to be a perfect assassin. X-23 later goes by the name Laura. She is eventually enrolled at the Xavier Institute. She quickly accepts Wolverine as a father figure, and eventually they learn that he is actually her biological father. Wolverine is brainwashed by the Hand and battles S.H.I.E.L.D., but eventually turns against them with the help of Elektra. After Scarlet Witch drastically transforms reality, Wolverine is able to recall memories of his previous life, overcoming his traumatic amnesia; he discovers that he has a son named Daken, who has been brainwashed and made a living weapon. Cyclops orders Wolverine to reform X-Force. Wolverine splits from Cyclops and opens a new school in Westchester, New York, the "Jean Grey School for Higher Learning". The Phoenix Force returns to Earth, causing conflict between the X-Men and the Avengers. Wolverine takes the side of the Avengers. Cyclops becomes possessed by the Phoenix Force and kills Professor X. A virus turns off Wolverine's healing factor. He discovers that Doctor Abraham Cornelius, the founder of the Weapon X program, has placed a bounty on his head. Wolverine gets covered in adamantium after confronting him, and dies from suffocation. Laura begins wearing a variation of Wolverine's costume and adopts his codename. Wolverine is eventually resurrected by Persephone, a mutant who can raise the dead.
The second approach utilizes diethyl carbonate in the presence of a strong base to give α-phenylcyanoacetic ester. Alkylation of this ester using ethyl bromide proceeds via a nitrile anion intermediate to give the α-phenyl-α-ethylcyanoacetic ester. This product is then further converted into the 4-iminoderivative upon condensation with urea. Finally acidic hydrolysis of the resulting product gives phenobarbital.
===== Human T-lymphotropic virus (types I and II) ===== Human T-Lymphotrophic Virus (HTLV) is able to be passed through breastmilk from mother to child. The worldwide rate of transmission through breastmilk is estimated to be 3.9–27%, and this risk is increased by high maternal viral load and prolonged periods of breastfeeding. Current data demonstrates that while breastfeeding for less than six months does not, independently, increase risk of HTLV-1 transmission, not breastfeeding during that time does decrease risk of transmission. As such, CDC recommends against breastfeeding when mothers have HTLV Types I or II. Recognizing the importance of breastfeeding in more resource-poor areas of the world, the World Health Organization recommends shortening the duration of breastfeeding, or avoiding breastfeeding where possible.
J. League Manager of the Year: 1995 Onze d'Or Coach of The Year: 2000, 2002, 2003, 2004 Premier League Manager of the Season: 1997–98, 2001–02, 2003–04 LMA Manager of the Year: 2001–02, 2003–04 BBC Sports Personality of the Year Coach Award: 2002, 2004 London Football Awards – Outstanding Contribution to a London Club: 2015 World Soccer Manager of the Year: 1998 FWA Tribute Award: 2005 English Football Hall of Fame: 2006 France Football Manager of the Year: 2008 IFFHS World Coach of the Decade: 2001–2010 Facebook FA Premier League Manager of the Year: 2014–15 Premier League Manager of the Month: March 1998, April 1998, October 2000, April 2002, September 2002, August 2003, February 2004, August 2004, September 2007, December 2007, February 2011, February 2012, September 2013, March 2015, October 2015 France Football 32nd Greatest Manager of All Time: 2019 World Soccer 36th Greatest Manager of All Time: 2013 Laureus Lifetime Achievement Award: 2019 Premier League Hall of Fame: 2023 Orders
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
RP-HPLC is widely used for purity and impurity profiling. Mass spectrometry confirms identity.